Physician Views snap-poll: Asking cardiologists to assess AstraZeneca's new Farxiga data for heart failure

AstraZeneca's Farxiga has become the first SGLT2 inhibitor to demonstrate a pronounced cardiovascular (CV) benefit in patients with and without type 2 diabetes; suggesting a potential broadening of its commercial profile. Detailed results from the DAPA-HF study were presented at the annual meeting of the European Society of Cardiology (ESC) on Sunday.

Commenting on previously announced top-line data, a leading expert told FirstWord that a reduction in CV risk across the whole study population would be practice changing.

The biggest challenge will likely be convincing cardiologists to change their treatment practice to incorporate a drug initially developed and approved to treat diabetes. To get a better idea how this may play out, we are snap-polling cardiologists (based in the US, France, Germany and the UK) with the following questions…

_____________

Q. Do you routinely treat/manage heart failure in patients with reduced ejection fraction (HFrEF)?

Yes

No

_____________

Q. Results from the Phase III DAPA-HF trial show Farxiga/Forxiga (dapagliflozin) on top of standard of care reduced both the incidence of cardiovascular death and the worsening of heart failure in patients with reduced ejection fraction (HFrEF), with and without type 2 diabetes.

Results show Farxiga reduced the composite of cardiovascular death or worsening of heart failure by 26% (p<0.0001) and showed a reduction in each of the individual components of the composite endpoint. There was a 30% decrease (p<0.0001) in the risk of experiencing a first episode of worsening heart failure and an 18% decrease (p=0.0294) in the risk of dying from cardiovascular causes. The effect of Farxiga on the primary composite endpoint was generally consistent across the key subgroups examined, with equal efficacy demonstrated in patients whether they had type 2 diabetes or not.

The safety profile of Farxiga in the DAPA-HF trial was consistent with the well-established safety profile of the medicine. The proportion of patients with volume depletion (7.5% versus 6.8%) and renal adverse events (6.5% vs 7.2%), which are commonly of concern when treating heart failure, were comparable to placebo. Major hypoglycaemic events (0.2% versus 0.2%) were rare in both treatment groups.

How would you rate the clinical innovation of this product versus current standard-of-care therapy(s) for patients without type 2 diabetes?

1 - None

2

3

4 - Moderate

5

6

7 - Very high

_____________

Q. How would you rate this product as meeting an unmet clinical need in patients without type 2 diabetes?

1 - None

2

3

4 - Moderate

5

6

7 - Very high

_____________

Q. How would you rate your likelihood of using this product, if approved on the strength of available clinical data, in patients without type 2 diabetes?

1 - None

2

3

4 - Moderate

5

6

7 - Very high

_____________

Q. Assuming real-world use confirms the clinical profile of this drug (as per its clinical study data), how frequently would you expect to use versus current standard-of-care therapy(s) in patients without type 2 diabetes?

1 - None

2

3

4 - Moderately

5

6

7 - Very frequently

_____________

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views Poll Results articles, click here.